Company code: 603102 company abbreviation: Weihai Baihe Biotechnology Co., Ltd
Notes on undisclosed internal control evaluation report in 2021
I Construction of internal control system
Weihai Baihe Biotechnology Co., Ltd. (hereinafter referred to as "the company") has established an organizational structure to meet the development needs of the company in accordance with the company law of the people's Republic of China, the securities law of the people's Republic of China, the governance standards of listed companies, the Listing Rules of Shanghai Stock Exchange and other relevant laws and regulations and the articles of association, It has formulated the rules of procedure of the general meeting of shareholders, the rules of procedure of the board of directors, the rules of procedure of the board of supervisors, the working rules of the general manager, the working rules of independent directors and the working rules of the audit committee of the board of directors Rules of procedure of the nomination committee of the board of directors, rules of procedure of the remuneration and assessment committee of the board of directors, rules of procedure of the strategy committee of the board of directors, management system of external guarantee, management system of foreign investment, management system of related party transactions, working rules of the Secretary of the board of directors, management system of raised funds, management system of information disclosure, management system of investor relations and management system of regulating capital exchanges with related parties Basic rules and regulations such as the registration and management system of insiders to ensure the standardized operation of the company and promote the healthy development of the company. In the daily operation and management of the company, based on the basic system of the company, a series of internal management systems covering the whole production and operation process such as product sales, production management, human resources, administrative management and financial management have been formulated to ensure that all work has rules to follow and orderly management, forming a standardized management system.
The company will sort out, revise and improve the internal control system in time according to its own continuous development needs, further strengthen the construction of the company's internal control system, optimize the work process, reasonably prevent various business risks, and continuously improve the construction level of the company's internal control, so as to ensure the sustainable and steady development of the company and protect the legitimate rights and interests of the company and shareholders. II Description of non disclosure of annual internal control evaluation report 1. Is there any special situation of non mandatory disclosure
√ yes □ no
Special circumstances of non mandatory disclosure are: New Listing 2. Description of specific circumstances
The company was listed on the main board of Shanghai Stock Exchange on January 25, 2022. According to relevant regulations, "the newly listed main board listed company shall start to build the internal control system in the year of listing, and disclose the internal control self-evaluation report and audit report at the same time as the annual report of the next year of listing." The company is a newly listed company, so it has not disclosed the internal control evaluation report in 2021. The company will disclose the internal control evaluation report while disclosing the annual report of the next year.
Board of directors Weihai Lily Biotechnology Co., Ltd. April 19, 2022
